Claire E Raphael1, Judith A Finegold2, Anthony J Barron2, Zachary I Whinnett1, Jamil Mayet2, Cecilia Linde3, John G F Cleland4, Wayne C Levy5, Darrel P Francis2. 1. International Centre for Circulatory Health, National Heart Lung Institute, Imperial College, St. Mary's Hospital, London W2 1LA, UK claire.raphael@gmail.com z.whinnett@imperial.ac.uk. 2. International Centre for Circulatory Health, National Heart Lung Institute, Imperial College, St. Mary's Hospital, London W2 1LA, UK. 3. Department of Cardiology, Karolinska University, Stockholm, Sweden. 4. Royal Brompton and Harefield NHS Foundation Trust and National Heart Lung Institute, Imperial College, London, UK. 5. Division of Cardiology, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: In at-risk patients with left ventricular dysfunction, implantable cardioverter defibrillators (ICDs) prolong life. Implantable cardioverter defibrillators are increasingly implanted for primary prevention and therefore into lower risk patients. Trial data have demonstrated the benefit of these devices but does not provide an estimate of potential lifespan-gain over longer time periods, e.g. a patient's lifespan. METHODS: Using data from landmark ICD trials, lifespan-gain was plotted against baseline annual mortality in the individual trials. Lifespan-gain was then extrapolated to a time-horizon of >20 years while adjusting for increasing 'competing' risk from ageing and non-sudden cardiac death (pump failure). RESULTS: At 3 years, directly observed lifespan-gain was strongly dependent on baseline event rate (r = 0.94, P < 0.001). However, projecting beyond the duration of the trial, lifespan-gain increases rapidly and non-linearly with time. At 3 years, it averages 1.7 months, but by 10 years up to 9-fold more. Lifespan-gain over time horizons >20 years were greatest in lower risk patients (∼5 life-years for 5% baseline mortality, ∼2 life-years for 15% baseline mortality). Increased competing risks significantly reduce lifespan-gain from ICD implantation. CONCLUSION: While high-risk patients may show the greatest short-term gain, the dramatic growth of lifespan-gain over time means that it is the lower risk patients, e.g. primary prevention ICD implantation, who gain the most life-years over their lifetime. Benefit is underestimated when only trial data are assessed as trials can only maintain randomization over limited periods. Lifespan-gain may be further increased through advances in ICD device programming. Published on behalf of the European Society of Cardiology. All rights reserved.
BACKGROUND: In at-risk patients with left ventricular dysfunction, implantable cardioverter defibrillators (ICDs) prolong life. Implantable cardioverter defibrillators are increasingly implanted for primary prevention and therefore into lower risk patients. Trial data have demonstrated the benefit of these devices but does not provide an estimate of potential lifespan-gain over longer time periods, e.g. a patient's lifespan. METHODS: Using data from landmark ICD trials, lifespan-gain was plotted against baseline annual mortality in the individual trials. Lifespan-gain was then extrapolated to a time-horizon of >20 years while adjusting for increasing 'competing' risk from ageing and non-sudden cardiac death (pump failure). RESULTS: At 3 years, directly observed lifespan-gain was strongly dependent on baseline event rate (r = 0.94, P < 0.001). However, projecting beyond the duration of the trial, lifespan-gain increases rapidly and non-linearly with time. At 3 years, it averages 1.7 months, but by 10 years up to 9-fold more. Lifespan-gain over time horizons >20 years were greatest in lower risk patients (∼5 life-years for 5% baseline mortality, ∼2 life-years for 15% baseline mortality). Increased competing risks significantly reduce lifespan-gain from ICD implantation. CONCLUSION: While high-risk patients may show the greatest short-term gain, the dramatic growth of lifespan-gain over time means that it is the lower risk patients, e.g. primary prevention ICD implantation, who gain the most life-years over their lifetime. Benefit is underestimated when only trial data are assessed as trials can only maintain randomization over limited periods. Lifespan-gain may be further increased through advances in ICD device programming. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Shireen Saxena; Ilan Goldenberg; Scott McNitt; Eileen Hsich; Valentina Kutyifa; Nicola Luigi Bragazzi; Bronislava Polonsky; Mehmet K Aktas; David T Huang; Spencer Rosero; Helmut Klein; Wojciech Zareba; Arwa Younis Journal: JAMA Netw Open Date: 2022-06-01
Authors: Anne G Raafs; Gerard C M Linssen; Jasper J Brugts; Ayten Erol-Yilmaz; Jacobus Plomp; Jeroen P P Smits; Michiel J Nagelsmit; Remko M Oortman; Arno W Hoes; Hans-Peter Brunner-LaRocca Journal: ESC Heart Fail Date: 2020-05-12